Progesterone in Gender Affirming Hormone Therapy Study
NCT06807580 is a phase 2 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is recruiting participants. It studies Placebo and Progesterone in Transgender Women. The registry lists an enrollment of 40 participants at 1 site in 1 country. The registry lists a start date of 12 May 2025 and a primary completion date of 28 Feb 2027.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06807580 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Emory University |
| Enrollment | 40 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Transgender Women |
| Drugs | Placebo and Progesterone |
| Start | 12 May 2025 |
| Primary completion | 28 Feb 2027 |
| Study completion | 28 Feb 2027 |
| Last update posted | 24 Dec 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Vin Tangpricha, MD, PhD
Emory University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory Transgender Clinic
Atlanta
Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06807580
Each answer restates registry values shown on this page.
What is NCT06807580?
NCT06807580 is a phase 2 interventional trial sponsored by Emory University. It studies Placebo and Progesterone in Transgender Women.
Is NCT06807580 recruiting?
As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT06807580?
The registry names Vin Tangpricha, MD, PhD (principal investigator, Emory University) as the overall official.
Where does NCT06807580 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06807580 study?
The registered drug and biological interventions are Placebo and Progesterone.
When is NCT06807580 expected to complete?
The registry lists a primary completion date of 28 Feb 2027 and a study completion date of 28 Feb 2027. The sponsor last updated the record on 24 Dec 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.